Lantern Pharma announces collaboration with Oregon Therapeutics to advance AI-driven cancer drug development
Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the development of XCE853, a first-in-class protein disulfide ... Read More
Lantern Pharma gets FDA nod for LP-284 clinical trial in non-Hodgkin’s lymphoma
Lantern Pharma Inc. (NASDAQ: LTRN), a trailblazer in artificial intelligence (AI) and machine learning (ML) for targeted cancer therapies, has received clearance from the United ... Read More
Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300
Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with its Harmonic phase 2 clinical trial of ... Read More
Lantern Pharma bags FDA orphan drug status for LP-184 in pancreatic cancer
Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food and Drug Administration (FDA) for the treatment ... Read More